Treatment and vision-related quality of life in the early manifest glaucoma trial
(2005) In Ophthalmology 112(9). p.1505-1513- Abstract
- Purpose: To evaluate the effect of treatment, visual function, and other factors on vision-targeted health-related quality of life (HRQOL) of patients with early glaucoma. Design: Randomized clinical trial. Participants: Two hundred fifty-five patients with newly detected open-angle glaucoma and repeatable early visual field (VF) defects, 50 to 80 years old (66% female). Methods: Patients were randomized to receive either betaxolol plus laser trabeculoplasty ineligible eye(s) or no initial treatment and had ophthalmologic examinations every 3 months. A Swedish translation of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was self-administered at 2 follow-up visits (3 and 6 years after randomization). Main... (More)
- Purpose: To evaluate the effect of treatment, visual function, and other factors on vision-targeted health-related quality of life (HRQOL) of patients with early glaucoma. Design: Randomized clinical trial. Participants: Two hundred fifty-five patients with newly detected open-angle glaucoma and repeatable early visual field (VF) defects, 50 to 80 years old (66% female). Methods: Patients were randomized to receive either betaxolol plus laser trabeculoplasty ineligible eye(s) or no initial treatment and had ophthalmologic examinations every 3 months. A Swedish translation of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was self-administered at 2 follow-up visits (3 and 6 years after randomization). Main Outcome: Multiple linear regression analyses determined the effect of treatment and other factors on (1) VFQ-25 composite scores at the first administration and (2) change in scores between administrations. Results: Two hundred thirty-three patients had 1 NEI VFQ-25 administration and 167 patients had 2 administrations. Internal consistency reliability was high for the composite VFQ-25 score (Cronbach alpha = 0.88) and satisfactory (alpha >= 0.76) for most subscale scores. At the first administration, the composite score was high (88.8 +/- 11.7). Mean subscale scores were also generally high (98.0-58.3) and were similar for each study group when analyzed separately. Most lower subscale scores were modestly but significantly related to worse visual acuity (VA) or mean deviation (MD) (better eye, r = 0.15-0.35). Composite scores were similar for treated and untreated patients. Lower composite scores were associated with low VA in the better eye (worse than 0.70) and worse perimetric MD (< 4.16 decibels) and nuclear lens opacities (Lens Opacities Classification System 11 grade ! 2), but not with age, gender, VF progression, intraocular pressure, cardiovascular disease, or hypertension. Between VFQ-25 administrations, larger decreases in the composite score were associated with larger decreases in VA (P < 0.05), female gender (P = 0.001), and older age at first administration (P = 0.006). Treatment (assigned at randomization or later in the study) was not associated with change in HRQOL. Conclusions: Results suggest that absence or delay of treatment did not influence vision-targeted HRQOL in these newly diagnosed glaucoma patients. However, visual function affected vision-targeted quality of life up to 6 years after Early Manifest Glaucoma Trial enrollment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/892068
- author
- Hyman, LG ; Komaroff, E ; Heijl, Anders LU ; Bengtsson, Bo LU and Leske, MC
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Ophthalmology
- volume
- 112
- issue
- 9
- pages
- 1505 - 1513
- publisher
- Elsevier
- external identifiers
-
- wos:000231544200005
- pmid:16019074
- scopus:24944562844
- ISSN
- 1549-4713
- DOI
- 10.1016/j.ophtha.2005.03.028
- language
- English
- LU publication?
- yes
- id
- d0c87cbc-2872-4c65-aee5-792cef97b9a0 (old id 892068)
- date added to LUP
- 2016-04-01 11:50:59
- date last changed
- 2022-03-13 01:33:57
@article{d0c87cbc-2872-4c65-aee5-792cef97b9a0,
abstract = {{Purpose: To evaluate the effect of treatment, visual function, and other factors on vision-targeted health-related quality of life (HRQOL) of patients with early glaucoma. Design: Randomized clinical trial. Participants: Two hundred fifty-five patients with newly detected open-angle glaucoma and repeatable early visual field (VF) defects, 50 to 80 years old (66% female). Methods: Patients were randomized to receive either betaxolol plus laser trabeculoplasty ineligible eye(s) or no initial treatment and had ophthalmologic examinations every 3 months. A Swedish translation of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25) was self-administered at 2 follow-up visits (3 and 6 years after randomization). Main Outcome: Multiple linear regression analyses determined the effect of treatment and other factors on (1) VFQ-25 composite scores at the first administration and (2) change in scores between administrations. Results: Two hundred thirty-three patients had 1 NEI VFQ-25 administration and 167 patients had 2 administrations. Internal consistency reliability was high for the composite VFQ-25 score (Cronbach alpha = 0.88) and satisfactory (alpha >= 0.76) for most subscale scores. At the first administration, the composite score was high (88.8 +/- 11.7). Mean subscale scores were also generally high (98.0-58.3) and were similar for each study group when analyzed separately. Most lower subscale scores were modestly but significantly related to worse visual acuity (VA) or mean deviation (MD) (better eye, r = 0.15-0.35). Composite scores were similar for treated and untreated patients. Lower composite scores were associated with low VA in the better eye (worse than 0.70) and worse perimetric MD (< 4.16 decibels) and nuclear lens opacities (Lens Opacities Classification System 11 grade ! 2), but not with age, gender, VF progression, intraocular pressure, cardiovascular disease, or hypertension. Between VFQ-25 administrations, larger decreases in the composite score were associated with larger decreases in VA (P < 0.05), female gender (P = 0.001), and older age at first administration (P = 0.006). Treatment (assigned at randomization or later in the study) was not associated with change in HRQOL. Conclusions: Results suggest that absence or delay of treatment did not influence vision-targeted HRQOL in these newly diagnosed glaucoma patients. However, visual function affected vision-targeted quality of life up to 6 years after Early Manifest Glaucoma Trial enrollment.}},
author = {{Hyman, LG and Komaroff, E and Heijl, Anders and Bengtsson, Bo and Leske, MC}},
issn = {{1549-4713}},
language = {{eng}},
number = {{9}},
pages = {{1505--1513}},
publisher = {{Elsevier}},
series = {{Ophthalmology}},
title = {{Treatment and vision-related quality of life in the early manifest glaucoma trial}},
url = {{http://dx.doi.org/10.1016/j.ophtha.2005.03.028}},
doi = {{10.1016/j.ophtha.2005.03.028}},
volume = {{112}},
year = {{2005}},
}